Barbara Gayle Duncan - Apr 8, 2022 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Director
Signature
/s/ Danielle Mann for Barbara Duncan by PoA
Stock symbol
OVID
Transactions as of
Apr 8, 2022
Transactions value $
$0
Form type
4
Date filed
4/12/2022, 04:55 PM
Previous filing
Feb 4, 2022
Next filing
Jun 22, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +21.3K $0.00 21.3K Apr 8, 2022 Common Stock 21.3K $3.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.